Financial Planning Hawaii Inc. Takes Position in Amgen Inc. $AMGN

Financial Planning Hawaii Inc. purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 6,180 shares of the medical research company’s stock, valued at approximately $2,023,000. Amgen makes up about 1.2% of Financial Planning Hawaii Inc.’s portfolio, making the stock its 20th largest position.

A number of other institutional investors have also recently bought and sold shares of the business. Board of the Pension Protection Fund acquired a new stake in shares of Amgen during the 4th quarter valued at about $26,000. Howard Hughes Medical Institute acquired a new position in Amgen in the second quarter worth about $32,000. Olistico Wealth LLC bought a new position in Amgen during the fourth quarter worth about $33,000. Cloud Capital Management LLC bought a new position in Amgen during the third quarter worth about $34,000. Finally, Saranac Partners Ltd acquired a new stake in Amgen during the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the subject of a number of recent research reports. Freedom Capital cut Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Cantor Fitzgerald boosted their price target on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Mizuho increased their price objective on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Oppenheimer set a $400.00 price objective on Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Finally, Royal Bank Of Canada boosted their target price on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Price Performance

Shares of AMGN stock opened at $349.00 on Tuesday. The stock’s fifty day moving average is $362.96 and its 200-day moving average is $331.05. The stock has a market capitalization of $188.14 billion, a PE ratio of 24.53, a PEG ratio of 3.46 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the prior year, the firm earned $5.31 EPS. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.